Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.41 |
| ▸ | KLK7 | P49862 | 1/20 | 0.40 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.40 |
| ▸ | GLP1R | P43220 | 5/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18798881 | 1.00 | TDP1 (0.42) | TDP1ATMPOLBMEN1KMT2A | |
| SCHEMBL16909068 | 0.91 | GLP1R (0.48) | TDP1ATMMEN1KMT2AGLP1R | |
| SCHEMBL16908998 | 0.91 | GLP1R (0.48) | TDP1ATMMEN1KMT2AGLP1R | |
| SCHEMBL16921333 | 0.91 | GLP1R (0.39) | TDP1ATMPOLBMEN1KMT2A | |
| SCHEMBL3485748 | 0.88 | GLP1R (0.45) | TDP1ATMPOLBMEN1KMT2A | |
| SCHEMBL3485751 | 0.88 | GLP1R (0.45) | TDP1ATMPOLBMEN1KMT2A | |
| SCHEMBL18798879 | 0.86 | GLP1R (0.46) | GLP1RCTSKCTSSCAPN1 | |
| SCHEMBL20975589 | 0.86 | GLP1R (0.44) | TDP1ATMMEN1KMT2AGLP1R | |
| SCHEMBL16909223 | 0.86 | GLP1R (0.50) | GLP1RCTSKCTSSCAPN1 | |
| SCHEMBL16924990 | 0.86 | GLP1R (0.46) | GLP1RCTSKCTSSCAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9636298-B2 | Prodrugs of compounds that enhance antifungal activity and compositions of said prodrugs | METHYLGENE INC (CA) | 2017-05-02 | — | — | US | disclosed |
| US-20150203517-A1 | Prodrugs of Compounds that Enhance Antifungal Activity and Compositions of Said Prodrugs | METHYLGENE INC (CA) | 2015-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203517-A1 | Prodrugs of Compounds that Enhance Antifungal Activity and Compositions of Said Prodrugs | HDAC5, HDAC1, HDAC3 | TDP1 1097/4885ATM 3444/4885POLB 1992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.